Table 4. Anticancer drugs associations most often prescribed to patients in the study.

Main anticancer drugs associations	No. of prescriptions	Percent of prescription (%)	Need for dosage adjustment in RI	Potential nephrotoxicity
Cyclophosphamide–epirubicin–fluorouracil	80	7.4	Yes–No–No	No–SC–No
Fluorouracil–oxaliplatine	53	4.9	No–No	No–Yes
Fluorouracil–irinotecan	36	3.3	No–No	No–Yes
Carboplatin–paclitaxel	27	2.5	Yes–No	Yes–SC
Letrozole–zoledronate	26	2.4	No–Yes	No–Yes
Tamoxifen–zoledronate	23	2.1	No–Yes	SC–Yes
Cisplatine–gemcitabine	21	1.9	Yes–No	Yes–Yes
Cisplatine–fluorouracil	20	1.8	Yes–No	Yes–No
Exemestane–zoledronate	16	1.5	No–Yes	No–Yes
Docetaxel–zoledronate	14	1.3	Yes–Yes	No–Yes

Abbreviations: RI=renal insufficiency; SC=sparse cases.